View Item 

Show simple item record

Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field
dc.contributor.authorFatehi, Leilien_US
dc.contributor.authorWolf, Susan M.en_US
dc.contributor.authorMcCullough, Jeffreyen_US
dc.contributor.authorHall, Ralphen_US
dc.contributor.authorLawrenz, Francesen_US
dc.contributor.authorKahn, Jeffrey P.en_US
dc.contributor.authorJones, Cortneyen_US
dc.contributor.authorCampbell, Stephen A.en_US
dc.contributor.authorDresser, Rebecca S.en_US
dc.contributor.authorErdman, Arthur G.en_US
dc.contributor.authorHaynes, Christy L.en_US
dc.contributor.authorHoerr, Robert A.en_US
dc.contributor.authorHogle, Linda F.en_US
dc.contributor.authorKeane, Moira A.en_US
dc.contributor.authorKhushf, Georgeen_US
dc.contributor.authorKing, Nancy M. P.en_US
dc.contributor.authorKokkoli, Efrosinien_US
dc.contributor.authorMarchant, Garyen_US
dc.contributor.authorMaynard, Andrew D.en_US
dc.contributor.authorPhilbert, Martinen_US
dc.contributor.authorRamachandran, Gurumurthyen_US
dc.contributor.authorSiegel, Ronald A.en_US
dc.contributor.authorWickline, Samuelen_US
dc.date.accessioned2013-02-12T19:01:03Z
dc.date.available2014-02-03T16:21:45Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationFatehi, Leili; Wolf, Susan M.; McCullough, Jeffrey; Hall, Ralph; Lawrenz, Frances; Kahn, Jeffrey P.; Jones, Cortney; Campbell, Stephen A.; Dresser, Rebecca S.; Erdman, Arthur G.; Haynes, Christy L.; Hoerr, Robert A.; Hogle, Linda F.; Keane, Moira A.; Khushf, George; King, Nancy M. P.; Kokkoli, Efrosini; Marchant, Gary; Maynard, Andrew D.; Philbert, Martin; Ramachandran, Gurumurthy; Siegel, Ronald A.; Wickline, Samuel (2012). "Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field." The Journal of Law, Medicine & Ethics 40(4). <http://hdl.handle.net/2027.42/96363>en_US
dc.identifier.issn1073-1105en_US
dc.identifier.issn1748-720Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96363
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleRecommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Fielden_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelLaw and Legal Studiesen_US
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelGovernment, Politics and Lawen_US
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum(University of Michigan)en_US
dc.contributor.affiliationum(University of Michigan)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(Washington University in St. Louis)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(Johns Hopkins University)en_US
dc.contributor.affiliationother(Washington University in St. Louis) *en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(Arizona State University)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(Wake Forest School of Medicine)en_US
dc.contributor.affiliationother(University of South Carolina)en_US
dc.contributor.affiliationother(University of Minnesota)en_US
dc.contributor.affiliationother(University of Wisconsin, Madison)en_US
dc.contributor.affiliationother(Nanocopoeia, Inc.)en_US
dc.identifier.pmid23289677en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96363/1/j.1748-720X.2012.00703.x.pdf
dc.identifier.doi10.1111/j.1748-720X.2012.00703.xen_US
dc.identifier.sourceThe Journal of Law, Medicine & Ethicsen_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention & National Institutes of Health (CDC/NIH), Biosafety in Microbiological and Biomedical Laboratories: Centers for Disease Control and Prevention, National Institutes of Health (5th ed. 2009), available at < http://www.cdc.gov/biosafety/publications/bmbl5/BMBL.pdf > (last visited October 18, 2012) [hereinafter CDC Biosafety].en_US
dc.identifier.citedreferenceEOP Assessment of NNI, supra note 32, at xiv.en_US
dc.identifier.citedreference42 U.S.C. §§ 4321 et seq. (1969).en_US
dc.identifier.citedreferenceS. Z. Rahman et al., “Pharmacoenvironmentology: A Component of Pharmacovigilance,” Environmental Health 6 ( 2007 ): article 20, available at < http://link.springer.com/article/10.1186/1476‐069X‐6‐20 > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceEnvironmental Protection Agency, “Pesticides; Policies Concerning Products Containing Nanoscale Materials; Opportunity for Public Comment,” Federal Register 76, no. 117 ( 2011 ): 35383 – 35395, at 35387.en_US
dc.identifier.citedreferenceEnvironmental Protection Agency, Expanded Protections for Subjects in Human Research Involving Pesticides, available at < http://www.epa.gov/oppfead1/guidance/human‐test.htm > (last visited October 18, 2012); Environmental Protection Agency, Office of the Science Advisor, “About the HSRB,” available at < http://www.epa.gov/hsrb/about.htm > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNIH Guidelines, supra note 78.en_US
dc.identifier.citedreferenceOffice of Biotechnology Activities, Frequently Asked Questions (FAQs) of Interest to IBCs, available at < http://oba.od.nih.gov/oba/ibc/FAQs/IBC_Frequently_Asked_Questions7.24.09.pdf > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceEOP Assessment of NNI, supra note 32, at 40.en_US
dc.identifier.citedreferenceSee HHS Announces Text4Health Task Force Recommendations and Global Partnership, HHS Press Office (2011), available at < http://www.hhs.gov/news/press/2011pres/09/20110919a.html > (last visited October 18, 2012); The White House, Office of the Press Secretary, “President Barack Obama Announces Key FDA Appointments and Tougher Food Safety Measures,” March 14, 2009, available at < http://www.whitehouse.gov/the_press_office/Weekly‐Address‐President‐Barack‐Obama‐Announces‐Key‐FDA‐Appointments‐and‐Tougher‐F/ > (last visited October 18, 2012) [hereinafter White House FDA Appointments]; Interagency Working Group on Import Safety, Import Safety: Action Plan Update, (2008), available at < http://archive.hhs.gov/importsafety/report/action‐update/actionplanupdate.pdf > (last visited October 18, 2012) [hereinafter Interagency Working Group on Import Safety]; Department of Health and Human Services, “HHS Dot Gov Task Force,” available at < http://www.hhs.gov/web/dgtf/ > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceSee Administration for Children & Families (ACF), Federal Interagency Work Group on Child Abuse & Neglect, available at < http://www.acf.hhs.gov/programs/cb/fediawg/ > (last visited October 18, 2012); White House FDA Appointments, supra note 165; Interagency Working Group on Import Safety, supra note 165; Executive Order 13439, “Establishing an Interagency Working Group on Import Safety,” Federal Register 72, no. 139 (2007): 40053–40055.en_US
dc.identifier.citedreferenceSee HHS Chart, supra note 22; EPA Chart, supra note 22; DOL Chart, supra note 22.en_US
dc.identifier.citedreferenceOffice for Human Research Protections, U.S. Department of Health and Human Services, Charter, Secretary's Advisory Committee on Human Research Protections, available at < http://www.hhs.gov/ohrp/sachrp/charter/index.html > (last visited October 18, 2012) [hereinafter SACHRP Charter].en_US
dc.identifier.citedreferenceOffice for Human Research Protections, U.S. Department of Health and Human Services, Secretary's Advisory Committee on Human Research Protections (SACHRP), available at < http://www.hhs.gov/ohrp/sachrp/index.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceSACHRP Charter, supra note 168.en_US
dc.identifier.citedreference5 U.S.C. Appendix 2 (1972).en_US
dc.identifier.citedreference5 U.S.C. Appendix 1 (1972); S. P. Croley and W. F. Funk, “The Federal Advisory Committee Act and Good Government,” Yale Journal on Regulation 14, no. 2 (1997): 451–557, at 461–465.en_US
dc.identifier.citedreferenceR. Steinbrook, “Science, Politics, and Federal Advisory Committees,” New England Journal of Medicine 350, no. 14 ( 2004 ): 1454 – 1460, at 1454.en_US
dc.identifier.citedreferenceM. H. Cardozo, “The Federal Advisory Committee Act in Operation,” Administrative Law Review 33 ( 1981 ): 1 – 62, at 3–4.en_US
dc.identifier.citedreferenceSee Steinbrook, supra note 173, at 1459; D. Michaels et al., “Advice without Dissent,” Science 298, no. 5594 (2002): 703, at 703.en_US
dc.identifier.citedreference5 U.S.C. Appendix 2 (1972).en_US
dc.identifier.citedreferenceNNI Strategic Plan, supra note 31, at 2.en_US
dc.identifier.citedreferenceEOP Assessment of NNI, supra note 32, at 40.en_US
dc.identifier.citedreferenceMichaels et al., supra note 175.en_US
dc.identifier.citedreferenceEOP Assessment of NNI, supra note 32, at 40–41.en_US
dc.identifier.citedreferenceHoldren et al., supra note 1, at 5.en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreferenceOffice of Biotechnology Activities, Appendix M, available at < http://oba.od.nih.gov/oba/rac/guidelines/appendix_m.htm > (last visited October 18, 2012) [hereinafter Appendix M].en_US
dc.identifier.citedreferenceKing, supra note 112, at 386.en_US
dc.identifier.citedreferenceSee Wolf and Jones, supra note 34, at 1451–1452.en_US
dc.identifier.citedreferenceJ. Timmermans Y. Zhao and J. van den Hoven, “Ethics and Nanopharmacy: Value Sensitive Design of New Drugs,” Nanoethics 5, no. 3 ( 2011 ): 269 – 283, at 279.en_US
dc.identifier.citedreferenceWolf and Jones, supra note 34, at 1461.en_US
dc.identifier.citedreferenceBawa, supra, note 122, at 232.en_US
dc.identifier.citedreferenceB. Fadeel and A. E. Garcia‐Bennett, “Better Safe Than Sorry: Understanding the Toxicological Properties of Inorganic Nanoparticles Manufactured for Biomedical Applications,” Advanced Drug Delivery Reviews 62, no. 3 ( 2009 ): 362 – 374, at 370–371.en_US
dc.identifier.citedreferenceS. Harris, “The Regulation of Nanomedicine: Will the Existing Regulatory Scheme of the FDA Suffice?” Richmond Journal of Law & Technology 16, no. 2 ( 2009 ): article 4, 25 pages, at 18–19, 23.en_US
dc.identifier.citedreferenceP. Hoet et al., “Do Nanomedicines Require Novel Safety Assessments to Ensure Their Safety for Long‐Term Human Use?” Drug Safety 32, no. 8 ( 2009 ): 625 – 636, at 632.en_US
dc.identifier.citedreferenceR. Bawa and S. Johnson, “Emerging Issues in Nanomedicine and Ethics,” in F. Allhoff and P. Lin eds., Nanotechnology & Society ( Dordrecht, The Netherlands: Springer, 2008 ): 207 – 223, at 212–213.en_US
dc.identifier.citedreferenceK. A. Deville, “Law, Regulation and the Medical Use of Nanotechnology,” in F. Jotterand ed., Emerging Conceptual, Ethical and Policy Issues in Biotechnology ( Dordrecht, The Netherlands: Springer, 2008 ): 181 – 200, at 192–193.en_US
dc.identifier.citedreferenceN. Staggers et al., “Nanotechnology: The Coming Revolution and Its Implications for Consumers, Clinicians, and Informatics,” Nursing Outlook 56, no. 5 ( 2008 ): 268 – 274, at 273.en_US
dc.identifier.citedreferenceJ. Virdi, “Bridging the Knowledge Gap: Examining Potential Limits in Nanomedicine,” Spontaneous Generations 2, no. 1 ( 2008 ): 25 – 44, at 32.en_US
dc.identifier.citedreferenceC. Lenk and N. Biller‐Andorno, “Nanomedicine: Emerging or Re‐emerging Ethical Issues? A Discussion of Four Ethical Themes,” Medicine, Health Care and Philosophy 10, no. 2 ( 2007 ): 173 – 184, at 181.en_US
dc.identifier.citedreferenceD. B. Resnik and S. S. Tinkle, “Ethics in Nanomedicine,” Nanomedicine 2, no. 3 ( 2007 ): 345 – 350.en_US
dc.identifier.citedreferenceFDA Application of Nanotechnology, supra note 63.en_US
dc.identifier.citedreferenceFood and Drug Administration, U.S. Department of Health and Human Services, Science and Research Special Topics, available at < http://www.fda.gov/ScienceResearch/Special‐Topics/default.htm > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceCDER Manual of Policies and Procedures, supra note 25, at 3.en_US
dc.identifier.citedreferenceNational Institutes of Health, U.S. Department of Health and Human Services, Nanotechnology at the National Institutes of Health: Innovative Medical Research at the Molecular Scale, NIH Publication no. 08–6443 (2008): 1–8, at 1, available at < http://www.nih.gov/science/nanotechnology/pub_NANO_brochure.pdf > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNational Cancer Institute, Learn About Nanotechnology in Cancer, available at < http://nano.cancer.gov/learn/ > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceU.S. Department of Health and Human Services, Centers of Cancer Nanotechnology Excellence (CCNEs)(U54), available at < http://grants.nih.gov/grants/guide/rfa‐files/RFA‐CA‐09‐012.html > (last visited October 18, 2012). See, e.g., National Institutes of Health, Cancer Nanotechnology Platform Partnerships, available at < http://grants.nih.gov/grants/guide/rfa‐files/rfa‐ca‐05‐026.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNational Institute of Environmental Health Sciences, National Institutes of Health, Since You Asked – Nanotechnology and NIEHS, available at < http://www.niehs.nih.gov/health/topics/agents/sya‐nano/index.cfm > (last visited November 5, 2012).en_US
dc.identifier.citedreferenceEnvironmental Protection Agency, Extramural Research: Nanotechnology, available at < http://www.epa.gov/ncer/nano/questions/index.html > (last visited October 18, 2012); see EPA Nanoscale Materials, supra note 27.en_US
dc.identifier.citedreferenceW. Jordan, Office of Pesticide Programs, Nanotechnology and Pesticides, Pesticide Program Dialogue Committee Meeting, April 29, 2010, at 5, available at < http://www.epa.gov/pesticides/ppdc/2010/april2010/session1‐nanotec.pdf > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceOccupational Safety and Health Administration, “Safety and Health Topics: Nanotechnology,” available at < http://www.osha.gov/dsg/nanotechnology/nanotechnology.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNIOSH Approaches to Safe Nanotechnology, supra note 22.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 50, 63.en_US
dc.identifier.citedreferenceWolf and Jones, supra note 34, at 1450.en_US
dc.identifier.citedreferenceFood and Drug Administration, U.S. Department of Health and Human Services, Guidance for Industry and Researchers: The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application (August 2010): at 2, available at < http://www.fda.gov/downloads/Drugs/.../Guidances/UCM163892.pdf > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceA. D. Maynard, “Don't Define Nanomaterials,” Nature 475, no. 7354 ( 2011 ): 31. See also J. P. Holdren, C. R. Sunstein, and I. A. Siddiqui, “Policy Principles for the U.S. Decision‐Making Concerning Regulation and Oversight of Applications of Nanotechnology and Nanomaterials,” Memorandum for the Heads of Executive Departments and Agencies, Executive Office of the President (June 2011): at 3, available at < http://www.whitehouse.gov/sites/default/files/omb/inforeg/for‐agencies/nanotechnology‐regulation‐and‐oversight‐principles.pdf > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceV. K. Varadan L. Chen and J. Xie, Nanomedicine: Design and Applications of Magnetic Nanomaterials, Nonsensors and Nanosystems ( Chichester, West Sussex, UK: John Wiley and Sons, 2008 ): at 1 – 2; V. S. Chan, “Nanomedicine: An Unresolved Regulatory Issue,” Regulatory Toxicology & Pharmacology 46, no. 3 (2006): 218–224, at 219.en_US
dc.identifier.citedreferenceN. Sadrieh and T. J. Miller, “Nanotechnology: Regulatory Perspective for Drug Development in Cancer Therapeutics,” in M. M. Amiji ed., Nanotechnology for Cancer Therapy ( Boca Raton, FL: Taylor & Francis Group, 2007 ): 139 – 156, at 141; C. H. Stickland, “Nano‐Based Drugs and Medical Devices: FDA's Track Record,” Nanotechnology Law & Business 4, no. 2 (2007): 179–188, at 182.en_US
dc.identifier.citedreferenceM. L. Etheridge et al., “The Big Picture on Nanomedicine: The State of Investigational and Approved Nanomedicine Products,” Nanomedicine: Nanotechnology, Biology and Medicine (in press), available at < http://www.sciencedirect.com/science/article/pii/S1549963412002882 > (last visited November 28, 2012).en_US
dc.identifier.citedreference21 C.F.R. parts 50, 56 (2012).en_US
dc.identifier.citedreference45 C.F.R. part 46 (2011).en_US
dc.identifier.citedreference21 C.F.R. § 56.111 (2012); 45 C.F.R. § 46.111 (2011).en_US
dc.identifier.citedreference21 U.S.C. §§ 301 et seq. (2006).en_US
dc.identifier.citedreferenceM. S. Lesney, “A New Broom?” Modern Drug Discovery 3, no. 9 ( 2000 ): 31 – 33, available at < http://pubs.acs.org/subscribe/archive/mdd/v03/i09/html/Clinical1.html > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceU.S. Department of Health and Human Services, Federal Policy for the Protection of Human Subjects (‘Common Rule’), available at < http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html > (last visited October 17, 2012).en_US
dc.identifier.citedreference45 C.F.R. § 46.103 (2011).en_US
dc.identifier.citedreferenceU.S. Department of Health and Human Services, About OHRP, available at < http://www.hhs.gov/ohrp/about/index.html > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceOffice for Human Research Protections, U.S. Department of Health and Human Services, IRB Guidebook, at Chapter IV, available at < http://www.hhs.gov/ohrp/archive/irb/irb_guidebook.htm > (last visited October 17, 2012); R. Barke, “Balancing Uncertain Risks and Benefits in Human Subjects Research,” Science, Technology & Human Values 34, no. 3 (2009): 337–364, at 345–346.en_US
dc.identifier.citedreference21 C.F.R. part 314 (2012).en_US
dc.identifier.citedreference21 C.F.R. part 814 (2012). See generally U.S. Department of Health and Human Services, Food and Drug Administration, Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force (2007), available at < http://www.fda.gov/downloads/scienceresearch/specialtopics/nanotechnology/ucm110856.pdf > (last visited October 17, 2012) [hereinafter FDA Nanotechnology Task Force Report].en_US
dc.identifier.citedreference21 C.F.R. part 312 (2012).en_US
dc.identifier.citedreference21 C.F.R. part 812 (2012).en_US
dc.identifier.citedreference21 C.F.R. part 812 (2012); U.S. Health and Human Services, Food and Drug Administration, U.S. Department of Health and Human Services, IDE Responsibilities, available at < http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm046702.htm > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceFDA Nanotechnology Task Force Report, supra note 15, at 32.en_US
dc.identifier.citedreference42 C.F.R. §§ 52a, 52h.4 (2011). The terms “Scientific Review Group” and “Peer Review Group” are used interchangeably. 42 C.F.R. § 52h.2 (u) (2011).en_US
dc.identifier.citedreference42 C.F.R. § 52h.8 (2011).en_US
dc.identifier.citedreferenceSee National Institute for Occupational Safety and Health, U.S. Department of Health and Human Services, Approaches to Safe Nanotechnology: Managing the Health and Safety Concerns Associated with Engineered Nanomaterials (2009), available at < http://www.cdc.gov/niosh/docs/2009‐125/pdfs/2009‐125.pdf > (last visited October 17, 2012) [hereinafter NIOSH Approaches to Safe Nanotechnology]; Department of Labor, Organizational Chart, available at < http://www.dol.gov/dol/about‐dol/orgchart.htm > (last visited October 17, 2012) [hereinafter DOL Chart]; Environmental Protection Agency, EPA Organizational Chart, available at < http://www.epa.gov/aboutepa/organization.html > (last visited October 17, 2012) [hereinafter EPA Chart]; U.S. Department of Health and Human Services, HHS Organizational Chart, available at < http://www.hhs.gov/about/orgchart/ > (last visited October 17, 2012) [hereinafter HHS Chart].en_US
dc.identifier.citedreferenceSee, e.g., Office of Biotechnology Activities, National Institutes of Health, Recombinant DNA Advisory Committee Meetings, “Minutes of Meeting September 15–17, 2010,” available at < http://oba.od.nih.gov/rdna_rac/rac_meetings.html > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceFDA Nanotechnology Taskforce Report, supra note 15, at 19, 30, and 35.en_US
dc.identifier.citedreferenceOffice of Pharmaceutical Science, Center for Drug Evaluation and Research, Manual of Policies and Procedures (MAPP), Reporting Format for Nanotechnology‐Related Information in CMC Review (June 2010): 4–5, available at < http://www.fda.gov/downloads/AboutFDA/CentersOffices/.../UCM214304.pdf > (last visited October 17, 2012) [hereinafter CDER Manual of Policies and Procedures].en_US
dc.identifier.citedreferenceFood and Drug Administration, U.S. Department of Health and Human Services, “Considering Whether an FDA‐Regulated Product Involves the Application of Nanotechnology,” Federal Register 76, no. 114 (June 14, 2011): 34715–34716.en_US
dc.identifier.citedreferenceSee NIOSH Approaches to Safe Nanotechnology, supra note 22; Environmental Protection Agency, “Pesticides; Policies Concerning Products Containing Nanoscale Materials; Opportunity for Public Comment,” Federal Register 76, no. 117 (June 17, 2011): 35383–35395 [hereinafter EPA Nanoscale Materials].en_US
dc.identifier.citedreferenceHoldren et al., supra note 1, at 5.en_US
dc.identifier.citedreferenceNational Research Council, Committee to Develop a Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterial, A Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials (Washington, DC: National Academies Press, 2012) [hereinafter NRC Research Strategy].en_US
dc.identifier.citedreferenceId., at 5.en_US
dc.identifier.citedreferenceNational Nanotechnology Initiative, National Science and Technology Council Committee on Technology Subcommittee on Nanoscale Science, and Technology, National Nanotechnology Initiative Strategic Plan (2011), at 30, available at < http://www.nano.gov/node/581 > (last visited October 17, 2012) [hereinafter NNI Strategic Plan].en_US
dc.identifier.citedreferenceExecutive Office of the President, PCAST Report to the President and Congress on the Fourth Assessment of the National Nanotechnology Initiative (2012), April 27, 2012, at 22–23, available at < http://nano.gov/node/786 > (last visited October 17, 2012) [hereinafter EOP Assessment of NNI].en_US
dc.identifier.citedreferenceSee, e.g., E. J. Emanuel et al., The Oxford Textbook of Clinical Research Ethics (New York: Oxford University Press, 2008); R. J. Levine, Ethics and Regulation of Clinical Research, 2nd ed. (New Haven: Yale University Press, 1988).en_US
dc.identifier.citedreferenceSee S. M. Wolf and C. M. Jones, “Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies,” Journal of Nanoparticle Research 13, no. 4 (2011): 1449–1465.en_US
dc.identifier.citedreferenceW. H. De Jong and P. J. Borm, “Drug Delivery and Nanoparticles: Applications and Hazards,” International Journal of Nanomedicine 3, no. 2 ( 2008 ): 133 – 149, at 139–140; W. H. De Jong et al., “Particle Size‐Dependent Organ Distribution of Gold Nanoparticles after Intravenous Administration,” Biomaterials 29, no. 12 (2008): 1912–1919, at 1913.en_US
dc.identifier.citedreferenceM. A. Dobrovolskaia and S. E. McNeil, “Immunological Properties of Engineered Nanomaterials,” Nature Nanotechnology 2, no. 8 ( 2007 ): 469 – 478, at 469.en_US
dc.identifier.citedreferenceN. Sanvicens and M. P. Marco, “Multifunctional Nanoparticles: Properties and Prospects for Their Use in Human Medicine,” Trends in Biotechnology 26, no. 8 ( 2008 ): 425 – 433, at 430; D. F. Emerich and C. G. Thanos, “Targeted Nanoparticle‐Based Drug Delivery and Diagnosis,” Journal of Drug Targeting 15, no. 3 (2007): 163–183, at 164.en_US
dc.identifier.citedreferenceV. Wiwanitkit A. Sereemaspun and R. Rojanathanes, “Effect of Gold Nanoparticles on Spermatozoa: The First World Report,” Fertility and Sterility 91, no. 1 ( 2009 ): e7 – e8.en_US
dc.identifier.citedreferenceL. Tran and J. M. Navas Anton, “Nanotoxicology and Engineered Nanoparticle Risk Assessment,” Seguridad y Medio Ambiente 29, no. 114 ( 2009 ): 1 – 45, at 3, available at < http://www.mapfre.com/fundacion/html/revistas/seguridad/n114/docs/Seguridad‐y‐Medio‐Ambiente‐114‐en.pdf > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceV. Murashov, “Occupational Exposure to Nanomedical Applications,” Nanomedicine and Nanobiotechnology 1, no. 2 ( 2009 ): 203 – 213.en_US
dc.identifier.citedreferenceG. Oberdörster, “Safety Assessment for Nanotechnology and Nanomedicine: Concepts of Nanotoxicology,” Journal of Internal Medicine 267, no. 1 ( 2010 ): 89 – 105, at 100; D. B. Warheit, “Debunking Some Misconceptions About Nanotoxicology,” Nano Letters 10, no. 12 (2010): 4777–4782, at 4781; D. B. Resnik and S. S. Tinkle, “Ethical Issues in Clinical Trials Involving Nanomedicine,” Contemporary Clinical Trials 28, no. 4 (2007): 433–441, at 436.en_US
dc.identifier.citedreferenceA. A. Shvedova and V. E. Kagan, “The Role of Nanotoxicology in Realizing the ‘Helping without Harm’ Paradigm of Nanomedicine: Lessons from Studies of Pulmonary Effects of Single‐Walled Carbon Nanotubes,” Journal of Internal Medicine 267, no. 1 ( 2010 ): 106 – 118; H. Fischer and W. Chan, “Nanotoxicity: The Growing Need for In Vivo Study,” Current Opinion in Biotechnology 18, no. 6 (2007): 565–571.en_US
dc.identifier.citedreferenceA. D. Maynard D. B. Warheit and M. A. Philbert, “The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond,” Toxicological Sciences 120, no. S1 ( 2011 ): S109 – S129.en_US
dc.identifier.citedreferenceWolf and Jones, supra note 34, at 1450.en_US
dc.identifier.citedreferenceSee, e.g., Institute of Medicine, D. D. Federman, K. E. Hanna, and L. L. Rodriguez, eds., Responsible Research: A Systems Approach to Protecting Research Participants (Washington, DC: National Academies Press, 2002): at 236.en_US
dc.identifier.citedreferenceHoldren et al., supra note 1, at 2.en_US
dc.identifier.citedreferenceWolf and Jones, supra note 34, at 1450.en_US
dc.identifier.citedreferenceS. Crowe, “Understanding the Ethical Implications of Nanotechnology: Highlights of a Limited Inquiry by the President's Council on Bioethics,” Staff Paper, President's Council on Bioethics (January 2008), available at < http://bioethics.georgetown.edu/pcbe/background/nanotechnology_implications.html > (last visited October 17, 2012).en_US
dc.identifier.citedreferenceM. Roco O. Renn and A. Jäger, “Nanotechnology Risk Governance,” in O. Renn and K. Walker eds., Global Risk Governance: Concept and Practice Using IRGC Framework ( Dordrecht, The Netherlands: Springer, 2008 ): 301 – 327, at 307.en_US
dc.identifier.citedreferenceSee generally, F. G. Miller and S. Joffe, “Limits to Research Risks,” Journal of Medical Ethics 35, no. 7 (2009): 445–449, at 448–449; S. Joffe and F. G. Miller, “Bench to Bedside: Mapping the Moral Terrain of Clinical Research,” Hastings Center Report 38, no. 2 (2008): 30–42, at 39–40.en_US
dc.identifier.citedreferenceMaynard, supra note 1, at 31.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 36–37.en_US
dc.identifier.citedreferenceMaynard, supra note 1, at 31.en_US
dc.identifier.citedreferenceNational Nanotechnology Initiative, About the NNI, available at < http://www.nano.gov/about‐nni > (last visited October 18, 2012); National Nanotechnology Initiative, NSET's Participating Federal Partners, available at < http://www.nano.gov/partners > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNational Nanotechnology Initiative, The NSET Subcommittee, available at < http://www.nano.gov/nset > (last visited October 18, 2012) [hereinafter NNI NSET].en_US
dc.identifier.citedreferenceNational Nanotechnology Initiative, What It Is and How It Works, available at < http://www.nano.gov/nanotech‐101/what > (last visited October 18, 2012) [hereinafter NNI What It Is]; National Nanotechnology Initiative, Frequently Asked Questions, available at < http://www.nano.gov/nanotech‐101/nanotechnology‐facts > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceCenter for Biological and Environmental Nanotechnology, CBEN Annual Report: Program Year 2009 (2009), available at < http://cben.rice.edu/uploadedFiles/Resource_Links/NSF%20Annual%20Report%20YR09%20‐%20ReverseSite‐Visit.pdf > (last visited October 18, 2012) [hereinafter CBEN Annual Report]; L. Goldenberg, “The ‘Integration/Penetration Model:’ Social Impacts of Nanobiotechnology Issues,” in M. C. Roco and W. S. Bainbridge, eds., Nanotechnology: Societal Implications II: Individual Perspectives (Dordrecht, The Netherlands: Springer, 2007): at 141–152.en_US
dc.identifier.citedreferenceJ. M. Balbus et al., “Getting It Right the First Time: Developing Nanotechnology While Protecting Workers, Public Health, and the Environment,” Annals of the New York Academy of Sciences 1076, no. 1 ( 2006 ): 331 – 342, at 333–334; M. Garnett and P. Kallinteri, “Nanomedicines and Nanotoxicology: Some Physiological Principles,” Occupational Medicine 56, no. 5 (2006): 307–311, at 310; V. Wagner et al., “The Emerging Nanomedicine Landscape,” Nature Biotechnology 24, no. 10 (2006): 1211–1217, at 1212.en_US
dc.identifier.citedreferenceA. G. Spagnolo and V. Daloiso, “Outlining Ethical Issues in Nanotechnologies,” Bioethics 23, no. 7 ( 2009 ): 394 – 402, at 399–400.en_US
dc.identifier.citedreferenceJ. W. Moore C. L. Stanitski and P. C. Jurs, Principles of Chemistry: The Molecular Science ( Belmont, CA: Brooks/Cole, Cengage Learning, 1st ed. 2010 ): at 16.en_US
dc.identifier.citedreferenceR. Brasseur J. Ruysschaert and P. Chatelain, “Semi‐Empirical Conformational Analysis of Propranolol Interacting with Dipalmitoylphosphatidylcholine,” Biochimica et Biophysica Acta (BBA) – Biomembranes 815, no. 3 ( 1985 ): 341 – 350, at 341, available at < http://www.sciencedirect.com.ezp1.lib.umn.edu/science/article/pii/0005273685903608 > (last visited August 21, 2012; restricted access).en_US
dc.identifier.citedreferenceW. J. Koolage and R. Hall, “Chemical Action: What Is It, and Why Does It Really Matter?” Journal of Nanoparticle Research 13, no. 4 ( 2011 ): 1401 – 1417, at 1416; Spagnolo and Daloiso, supra note 59, at 399.en_US
dc.identifier.citedreferenceCDER Manual of Policies and Procedures, supra note 25, at 3.en_US
dc.identifier.citedreferenceId., at 1.en_US
dc.identifier.citedreferenceFood and Drug Administration, Considering Whether an FDA‐Regulated Product Involves the Application of Nanotechnology, available at < http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm > (last visited October 18, 2012) (emphasis added) [hereinafter FDA Application of Nanotechnology].en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 49.en_US
dc.identifier.citedreferenceMaynard, supra note 1, at 31.en_US
dc.identifier.citedreferenceEtheridge et al., supra note 4.en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreferenceD. C. Litzinger et al., “Effect of Liposome Size on the Circulation Time and Intraorgan Distribution of Amphipathic Poly(ethylene glycol)‐containing Liposomes,” Biochimica et Biophysica Acta 1190, no. 1 ( 1994 ): 99 – 107, at 105.en_US
dc.identifier.citedreferenceEtheridge et al., supra note 4.en_US
dc.identifier.citedreferenceHoldren et al., supra note 1, at 5.en_US
dc.identifier.citedreferenceId., at 3.en_US
dc.identifier.citedreferenceBarke, supra note 13, at 341; J. Kimmelman, “Valuing Risk: The Ethical Review of Clinical Trial Safety,” Kennedy Institute of Ethics Journal 14, no. 4 (2004): 369–393, at 371.en_US
dc.identifier.citedreferenceD. M. Hausman, “Third‐Party Risks in Research: Should IRBs Address Them?” IRB 29, no. 3 ( 2007 ): 1 – 5, at 5; D. B. Resnik and R. R. Sharp, “Protecting Third Parties in Human Subjects Research,” IRB 28, no. 4 (2006): 1–7, at 3.en_US
dc.identifier.citedreferenceWolf and Jones, supra note 34, at 1450.en_US
dc.identifier.citedreferenceNational Institutes of Health, Frequently Asked Questions About the NIH Review Process for Human Gene Transfer Trials, available at < http://oba.od.nih.gov/rdna/rdna_faq.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNational Institutes of Health, NIH Guidelines for Research Involving Recombinant DNA ( 2011 ), available at < http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.htm > (last visited October 18, 2012) [hereinafter NIH Guidelines]. Note that changes in the NIH Guidelines to expand coverage to synthetic biology will go into effect in 2013. See National Institutes of Health, Final Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), Federal Register 77, no. 172 (2012): 54584–54597, available at < http://oba.od.nih.gov/oba/rac/fractions/77_FR_54584.pdf > (last visited November 13, 2012).en_US
dc.identifier.citedreferenceSee HHS Chart, supra note 22; EPA Chart, supra note 22; DOL Chart, supra note 22.en_US
dc.identifier.citedreferenceEtheridge et al., supra note 4.en_US
dc.identifier.citedreferenceE. M. Merisko‐Liversidge and G. G. Liversidge, “Drug Nanoparticles: Formulating Poorly Water‐Soluble Compounds,” Toxicologic Pathology 36, no. 1 ( 2008 ): 43 – 48, at 43–44.en_US
dc.identifier.citedreferenceId., at 46.en_US
dc.identifier.citedreferenceRoco et al., supra note 49.en_US
dc.identifier.citedreferenceDe Jong and Borm, supra note 35, at 136–137; De Jong et al., supra note 35, at 1913.en_US
dc.identifier.citedreferenceDobrovolskaia and McNeil, supra note 36; Resnik and Tinkle, supra note 41; M. Geiser et al., “Ultrafine Particles Cross Cellular Membranes by Nonphagocytic Mechanisms in Lungs and in Cultured Cells,” Environmental Health Perspectives 113 (2005): 1555–1560; G. Oberdörster, E. Oberdörster, and J. Oberdörster, “Nanotoxicity: An Emerging Discipline Evolving for Studies of Ultrafine Particles,” Environmental Health Perspectives 113, no. 7 (2005): 823–839; P. H. M. Hoet, I. Bruske‐Hohlfield, and O. V. Salata, “Nanoparticles: Known and Unknown Health Risks,” Journal of Nanobiotechnology 2, no. 12 (2004): 1–15, available at < http://www.jnanobiotechnology.com/content/pdf/1477‐3155‐2‐12.pdf > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceShvedova and Kagan, supra note 42; Wiwanitkit et al., supra note 38, at e7‐e8; Fischer and Chan, supra note 42, at 565–566.en_US
dc.identifier.citedreferenceTran and Navas Anton, supra note 39, at 1, 3.en_US
dc.identifier.citedreferenceOberdörster, supra note 41, at 102; D. B. Warheit, “Debunking Some Misconceptions about Nanotoxicology,” Nano Letters 10, no. 12 (2010): 4777–4782, at 4782.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 3; NNI Strategic Plan, supra note 31, at 18.en_US
dc.identifier.citedreferenceNNI Strategic Plan, supra note 31, at 18.en_US
dc.identifier.citedreferenceResnik and Tinkle, supra note 41, at 436.en_US
dc.identifier.citedreferenceNNI Strategic Plan, supra note 31, at 30–31, 48.en_US
dc.identifier.citedreferenceMaynard et al., supra note 43, at S111; Resnik and Tinkle, supra note 41, at 435–436; Oberdörster et al., supra note 85, at 836.en_US
dc.identifier.citedreferenceF. Graur et al., “Ethical Issues in Nanomedicine,” IFMBE Proceedings 36, no. 1 ( 2011 ): 9 – 12, at 10.en_US
dc.identifier.citedreferenceF. Jotterand and A. A. Alexander, “Managing the ‘Known Unknowns’: Theranostic Cancer Nanomedicine and Informed Consent,” in S. J. Hurst ed., Biomedical Nanotechnology (Methods in Molecular Biology, vol. 726) ( New York: Humana Press, 2011 ): 413 – 429, at 426.en_US
dc.identifier.citedreferenceJ. Kimmelman and A. J. London, “Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty,” PLoS Medicine 8, no. 3 ( 2011 ): e1001010 (5 pages), available at < http://dx.doi.org/10.1371%2Fjournal.pmed.1001010 > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceR. Chin and B. Y. Lee, Principles and Practice of Clinical Trial Medicine ( Burlington, MA: Elsevier, 1996 ): at 33 – 36.en_US
dc.identifier.citedreferenceCenter for Drug Evaluation and Research, Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies (2006), available at < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf > (last visited October 18, 2012) [hereinafter Exploratory IND Studies].en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreferenceSee R. Kinders et al., “Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice,” Molecular Interventions 7, no. 6 (2007): 325–334.en_US
dc.identifier.citedreferenceNNI Strategic Plan, supra note 31, at 30.en_US
dc.identifier.citedreferenceResnik and Tinkle, supra note 41, at 436.en_US
dc.identifier.citedreferenceKimmelman et al., supra note 50, at 1894; Resnik and Tinkle, supra note 41, at 436.en_US
dc.identifier.citedreferenceL. K. Aguilar and E. Aguilar‐Cordova, “Evolution of a Gene Therapy Clinical Trial,” Journal of Neuro-Oncology 65, no. 3 ( 2003 ): 307 – 315, at 312.en_US
dc.identifier.citedreferenceResnik and Tinkle, supra note 41, at 436–437.en_US
dc.identifier.citedreferenceKimmelman et al., supra note 50, at 1894.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 85.en_US
dc.identifier.citedreferenceShvedova and Kagan, supra note 42, at 108–109; Fischer and Chan, supra note 42, at 566.en_US
dc.identifier.citedreferenceJ. Kimmelman, Gene Transfer and the Ethics of First‐in Human Research: Lost in Translation ( New York: Cambridge University Press, 2010 ): at 21 – 22.en_US
dc.identifier.citedreferenceSee NIH Guidelines, supra note 78.en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreferenceN. M. P. King, “RAC Oversight of Gene Transfer Research: A Model Worth Extending?” Journal of Law, Medicine & Ethics 30, no. 3 ( 2002 ): 381 – 389, at 386.en_US
dc.identifier.citedreference21 C.F.R. § 50.25 (2012); 45 C.F.R. § 46.116 (2011).en_US
dc.identifier.citedreference21 C.F.R. §§ 50.25(b)(1), 50.25(b)(5) (2012); 45 C.F.R. §§ 46.116(b)(1), 46.116(b)(5) (2011).en_US
dc.identifier.citedreferenceWiwanitkit et al., supra note 38, at e8.en_US
dc.identifier.citedreferenceG. E. Henderson et al., “Clinical Trials and Medical Care: Defining the Therapeutic Misconception,” PLoS Medicine 4, no. 11 ( 2007 ): e324, 1735–1738, available at < http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1113&context=psych_cmhsr > (last visited October 18, 2012); F. G. Miller and H. Brody, “A Critique of Clinical Equipoise: Therapeutic Misconception in the Ethics of Clinical Trials,” Hastings Center Report 33, no. 3 (2003): 19–28; S. Hornig and C. Grady, “Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, and Therapeutic Optimism,” IRB 25, no. 1 (2003): 11–16; P. S. Appelbaum, L. H. Roth, and C. Lidz, “The Therapeutic Misconception: Informed Consent in Psychiatric Research,” International Journal of Law and Psychiatry 5, no. 3–4 (1982): 319–329.en_US
dc.identifier.citedreferenceP. S. Appelbaum C. W. Lidz and T. Grisso, “Therapeutic Misconception in Clinical Research: Frequency and Risk Factors,” IRB 26, no. 2 ( 2004 ): 1 – 8, at 4–5; C. W. Lidz et al., “Therapeutic Misconception and the Appreciation of Risks in Clinical Trials,” Social Science & Medicine 58, no. 9 (2004): 1689–1697, at 1695.en_US
dc.identifier.citedreferenceMiller and Brody, supra note 116, at 25–26.en_US
dc.identifier.citedreferenceJ. Kimmelman, “Ethics at Phase 0: Clarifying the Issues,” Journal of Law, Medicine & Ethics 35, no. 4 ( 2007 ): 727 – 733, at 729.en_US
dc.identifier.citedreferenceAppelbaum et al., supra note 117, at 7.en_US
dc.identifier.citedreferenceResnik and Tinkle, supra note 41, at 439.en_US
dc.identifier.citedreferenceR. Bawa, “Regulating Nanomedicine: Can the FDA Handle It?” Current Drug Delivery 8, no. 3 ( 2011 ): 227 – 234, at 229; R. Bawa and S. Johnson, “The Ethical Dimensions of Nanomedicine,” Medical Clinics of North America 91, no. 5 (2007): 881–887, at 882; T. T. Faunce and K. K. Shats, “Researching Safety and Cost‐Effectiveness in the Life Cycle of Nanomedicine,” Journal of Law & Medicine 15, no. 1 (2007): 128–135, at 131.en_US
dc.identifier.citedreferenceE.g., EuroNanoForum 2007: Nanotechnology in Industrial Applications, Nano Techwire website, August 21, 2006, available at < http://nanotechwire.com/news.asp?nid=3659 > (last visited October 18, 2012); M. D. Cobb and J. Macoubrie, “Public Perceptions about Nanotechnology: Risks, Benefits and Trust,” Journal of Nanoparticle Research 6, no. 4 (2004): 395–405.en_US
dc.identifier.citedreferenceT. Satterfield et al. “Anticipating the Perceived Risk of Nanotechnologies,” Nature Nanotechnology 4, no. 11 ( 2009 ): 752 – 758.en_US
dc.identifier.citedreferenceSee D. M. Berube, “The Public Acceptance of Nanomedicine: A Personal Perspective,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 1, no. 1 (2009): 2–5. See also B. Nerlich, D. D. Clarke, and F. Ulph, “Risks and Benefits of Nanotechnology: How Young Adults Perceive Possible Advances in Nanomedicine Compared with Conventional Treatments,” Health, Risk & Society 9, no. 2 (2007): 159–171.en_US
dc.identifier.citedreferenceBawa, supra note 122, at 230.en_US
dc.identifier.citedreferenceMaynard, supra note 1, at 31.en_US
dc.identifier.citedreference21 C.F.R. § 56.111(a)(g) (2012); 45 C.F.R. § 46.111(a)(6) (2011).en_US
dc.identifier.citedreference21 C.F.R. §§ 312.50, 312.56, 812.40, 812.46 (2012).en_US
dc.identifier.citedreferenceFood and Drug Administration, Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees ( 2006 ), available at < http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf > (last visited October 18, 2012) [hereinafter Guidance for Clinical Trial Sponsors].en_US
dc.identifier.citedreference21 C.F.R. §§ 312.56, 812.46 (2012).en_US
dc.identifier.citedreferenceGuidance for Clinical Trial Sponsors, supra note 130, at 3–4.en_US
dc.identifier.citedreferenceId., at 3–5.en_US
dc.identifier.citedreferenceNational Institutes of Health, Further Guidance on a Data and Safety Monitoring for Phase I and Phase II Trials (NOT‐OD‐00‐038) ( 2000 ), available at < http://grants.nih.gov/grants/guide/notice‐files/NOT‐OD‐00‐038.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNational Institutes of Health, NIH Policy for Data and Safety Monitoring (NOT‐98‐084) ( 1998 ), available at < http://grants.nih.gov/grants/guide/notice‐files/not98‐084.html > (last visited August 24, 2012).en_US
dc.identifier.citedreferenceA. S. Slutsky and J. V. Lavery, “Data Safety and Monitoring Boards,” New England Journal of Medicine 350, no. 11 ( 2004 ): 1143 – 1147, at 1143.en_US
dc.identifier.citedreferenceNNI Strategic Plan, supra note 31 at 29–32.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 78.en_US
dc.identifier.citedreferenceId., at 90.en_US
dc.identifier.citedreferenceV. Murashov and J. Howard, “Essential Features for Proactive Risk Management,” Nature Nanotechnology 4, no. 8 ( 2009 ): 467 – 470, at 467.en_US
dc.identifier.citedreferenceNRC Research Strategy, supra note 29, at 5; NNI Strategic Plan, supra note 31, at 27–32.en_US
dc.identifier.citedreference45 C.F.R. § 46.102 (2011).en_US
dc.identifier.citedreferenceHausman, supra note 75, at 3–5; Resnik and Sharp, supra note 75, at 3.en_US
dc.identifier.citedreferenceResnik and Sharp, supra note 75, at 3.en_US
dc.identifier.citedreferenceHausman, supra note 75, at 5.en_US
dc.identifier.citedreferenceId., at 4–5.en_US
dc.identifier.citedreferenceId., at 5; J. Kimmelman, “Missing the Forest: Further Thoughts on the Ethics of Bystander Risk in Medical Research,” Cambridge Quarterly of Healthcare Ethics 16, no. 4 (2007): 483–490, at 486–487; Resnik and Sharp, supra note 75, at 3.en_US
dc.identifier.citedreferenceResnik and Sharp, supra note 75, at 3.en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreference29 C.F.R. part 1910 (2012).en_US
dc.identifier.citedreferenceNIOSH Approaches to Safe Nanotechnology, supra note 22.en_US
dc.identifier.citedreferenceOccupational Safety and Health Administration, “Nanotechnology OSHA Standards,” available at < http://www.osha.gov/dsg/nanotechnology/nanotech_standards.html > (last visited August 20, 2012).en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention, Nanotechology: 10 Critical Topic Areas, available at < http://www.cdc.gov/niosh/topics/nanotech/critical.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention, Nanotechnology: Guidance and Publications, available at < http://www.cdc.gov/niosh/topics/nanotech/pubs.html > (last visited October 18, 2012).en_US
dc.identifier.citedreferenceNanoparticle Information Library, available at < http://nanoparticlelibrary.net/ > (last visited October 18, 2012).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1748-720X.2012.00703.x.pdf
Size:
4.374MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.